ContractCommercial License Agreement • January 15th, 2016 • Oncobiologics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledJanuary 15th, 2016 Company Industry[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
Commercial License AgreementCommercial License Agreement • October 9th, 2020 • Opthea LTD • Biological products, (no disgnostic substances)
Contract Type FiledOctober 9th, 2020 Company Industry
COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • June 19th, 2020 • Poseida Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
Contract Type FiledJune 19th, 2020 Company Industry JurisdictionThis Commercial License Agreement (“Agreement”) is entered into effective April 27, 2017 (“Effective Date”) by TeneoBio, Inc. (“TeneoBio”), having its principal place of business at 1490 O’Brien Drive, Suite D, Menlo Park, CA 94025, and Poseida Therapeutics, Inc. (“Licensee”), having its principal place of business at 4242 Campus Point Court, #700, San Diego, CA 92121. In consideration of the mutual covenants and promises set forth in this Agreement, the parties agree as follows:
CONFIDENTIAL TREATMENT REQUESTED. CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION.]Commercial License Agreement • July 12th, 2004 • Xenogen Corp • Services-commercial physical & biological research • California
Contract Type FiledJuly 12th, 2004 Company Industry JurisdictionThis Agreement (the “Agreement”) effective as of July 12, 2000 (the “Effective Date”) is made by and between Xenogen Corporation, having a principal place of business at 860 Atlantic Avenue, Alameda, California 94501 (“Xenogen”) and IRM, LLC, a Delaware Corporation, (“IRM”), having a principal place of business at Sofia House, 48 Church Street, Hamilton, Bermuda.
COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • April 10th, 2013 • BioAmber Inc. • Industrial organic chemicals
Contract Type FiledApril 10th, 2013 Company IndustryThis Commercial License Agreement (“Commercial License”), effective the 15th day of April, 2010 (“Effective Date”), is made by and between Cargill, Inc., through its Bio Technology Development Center, having its principal place of business at 15407 McGinty Road West, Wayzata, MN 55391 (hereinafter “Cargill”), and Bioamber S.A.S., having a place of business at Route de Bazancourt, F-51110, Pomacle France (“Bioamber”). Cargill and Bioamber are referred to herein as “Parties”, in singular or plural usage, as required by context.
COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • June 19th, 2020 • Poseida Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
Contract Type FiledJune 19th, 2020 Company Industry JurisdictionThis Commercial License Agreement (“Agreement”) is entered into effective August 3, 2018 (“Effective Date”) by TeneoBio, Inc. (“TeneoBio”), having its principal place of business at 1490 O’Brien Drive, Suite D, Menlo Park, CA 94025, and Poseida Therapeutics, Inc. (“Licensee”), having its principal place of business at 4242 Campus Point Court, #700, San Diego, CA 92121. In consideration of the mutual covenants and promises set forth in this Agreement, the parties agree as follows:
Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • July 8th, 2014 • Sage Therapeutics, Inc. • Pharmaceutical preparations • California
Contract Type FiledJuly 8th, 2014 Company Industry Jurisdictionavoidance of doubt, if the same Licensed Product first achieves one or more given milestones for two Additional Subfields, then the milestone payment for that event must be paid twice; and in no event shall the maximum payment under this Section 4.1(b)(ii) exceed $[…***…]) are as follows. Subject to the preceding sentence, if any such milestone is achieved in the relevant Additional Subfield before all prior sequential milestones have been actually achieved in such Additional Subfield, then any and all prior sequential milestones which were not previously actually achieved with respect to such Additional Subfield shall be deemed to have thereby been achieved, and the milestone payments for such deemed-achieved milestones shall also be payable with respect to such Additional Subfield within such […***…] days.
CONFIDENTIAL DEVELOPMENT COLLABORATION AND COMMERCIAL LICENSE AGREEMENT between MERSANA THERAPEUTICS, INC. and MILLENNIUM PHARMACEUTICALS, INC. dated January 29, 2016Commercial License Agreement • June 1st, 2017 • Mersana Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
Contract Type FiledJune 1st, 2017 Company Industry JurisdictionThis Development Collaboration and Commercial License Agreement is entered into as of the 29th day of January, 2016 by and between Mersana Therapeutics, Inc., a Delaware corporation, having its principal place of business at 840 Memorial Drive Cambridge, MA 02139 (hereinafter referred to as “Mersana”) and Millennium Pharmaceuticals, Inc., a Delaware corporation, having its principal place of business at 40 Landsdowne Street, Cambridge, MA 02139 (hereinafter referred to as “Licensee”).
BACKGROUNDCommercial License Agreement • January 26th, 2001 • Xenogen Corp • Services-commercial physical & biological research • California
Contract Type FiledJanuary 26th, 2001 Company Industry Jurisdiction
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO ELEVATION ONCOLOGY, INC. IF PUBLICLY DISCLOSED. COMMERCIAL LICENSE AGREEMENT ENTERED...Commercial License Agreement • May 14th, 2021 • Elevation Oncology, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMay 14th, 2021 Company IndustryWhereas, Merrimack is a biopharmaceutical company engaged in the research, development, manufacturing and sale of biopharmaceutical products; and
COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • July 3rd, 2017 • Calyxt, Inc. • Agricultural chemicals • New York
Contract Type FiledJuly 3rd, 2017 Company Industry JurisdictionTHIS COMMERCIAL LICENSE AGREEMENT (this “Agreement”) is made and entered into as of December 9, 2014 (the “Effective Date”), by and between Cellectis Plant Sciences, Inc. a corporation organized and existing under the laws of the State of Delaware with its principal place of business at 8, rue de la Croix Jarry, 75013 Paris, France (“CPS”), and Two Blades Foundation, a not-for-profit corporation organized and existing under the laws of the State of Delaware with its principal place of business at 1630 Chicago Avenue, Suite 1907, Evanston, IL 60201, USA (“2 Blades”; CPS and 2 Blades, each a “Party” and collectively, the “Parties”).
Pfēnex Expression Technology™ COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • January 23rd, 2006 • Iomai Corp • Pharmaceutical preparations • Delaware
Contract Type FiledJanuary 23rd, 2006 Company Industry JurisdictionThis Agreement is effective as of the latest date of signing below and is by and between Dow Global Technologies Incorporated (“Dow”), a Michigan corporation having its principal offices at 2030 Dow Center, Midland, MI, 48674 USA and Iomai Corporation, a Delaware corporation (“Licensee”) having a principal place of business at 20 Firstfield Road Suite 250, Gaithersburg, MD 20878 USA
COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • October 28th, 2020
Contract Type FiledOctober 28th, 2020BETWEEN : Katholieke Universiteit Leuven, for the purposes of this agreement represented by K.U. LEUVEN RESEARCH & DEVELOPMENT, with headquarters in Belgium at 3000 Leuven, Groot Begijnhof 58-59, and represented by Prof. Dr. ir. K. Debackere, Managing Director and Mr. P. Van Dun, Director,
COMMERCIAL LICENSE AGREEMENT FOR 2010 BACKBONE-DEPENDENT ROTAMER LIBRARY For a commercial license agreement and pricing, please contact Dr. Roland Dunbrack.Commercial License Agreement • May 5th, 2020
Contract Type FiledMay 5th, 2020ACADEMIC LICENSE AGREEMENT FOR 2010 BACKBONE-DEPENDENT ROTAMER LIBRARY Fox Chase Cancer Center (hereinafter known as FCCC) agrees to provide to Licensee a proprietary tool known as 2010 Backbone-Dependent Rotamer Library (hereinafter, BDRL) to use in various side-chain conformation prediction programs and to evaluate the likelihood that predicted or experimentally observed conformations of side-chains are correct. FCCC wishes to preserve to itself all of the property rights in and to BDRL, its related documentation and such enhancements thereto as may, from time to time, be made. Accordingly, FCCC and Licensee agree as follows:
COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • October 18th, 2019 • Virginia
Contract Type FiledOctober 18th, 2019 JurisdictionThis Enterprise Endpoint Management Platform, Data Collector, Data Management Node and Tactical TYCHON License Agreement (“Agreement”) describes the relationship between TYCHON, LLC (“Company”) and the licensee identified by the act of acquiring through an authorized transaction (“Licensee”) (collectively, the “Parties”) and includes the License Terms and Conditions and all Addenda that are separately executed by the Parties. This Agreement will become effective when this order is made and accepted by the Company or the distributor, reseller or other business partner (“Authorized Partner”) of Company.
RE: Letter AgreementCommercial License Agreement • January 15th, 2010 • Visualant Inc • Measuring & controlling devices, nec • Washington
Contract Type FiledJanuary 15th, 2010 Company Industry JurisdictionThis Non-Commercial License Agreement (this "Agreement"), dated as of October 23, 2008, is made by and between Visualant, Inc., a Nevada corporation ("Visualant") and RatLab, LLC, a Washington limited liability company ("RatLab"). Visualant and RatLab (sometimes referred to herein individually as a "Party" and collectively as the "Parties") therefore agree as follows:
AMSOL 7.1 COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • May 5th, 2020 • Minnesota
Contract Type FiledMay 5th, 2020 Jurisdiction__________________________________________________________________________ , and the Regents of the University of Minnesota (hereafter UNIVERSITY), a nonprofit corporation of the State of Minnesota, having an office at 450 McNamara Alumni Center, 200 Oak St. SE, Minneapolis, MN 55455-2070. The parties agree as follows:
COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • January 7th, 2011 • Visualant Inc • Measuring & controlling devices, nec • Washington
Contract Type FiledJanuary 7th, 2011 Company Industry JurisdictionThis Commercial License Agreement (this "Agreement"), dated as of January 3, 2011 (the "Effective Date"), is made by and between Visualant, Inc., a Nevada corporation ("Visualant") and Javelin, LLC, a Washington limited liability company ("Javelin"). Visualant and Javelin (sometimes referred to herein individually as a "Party" and collectively as the "Parties") therefore agree as follows:
COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • May 15th, 2023 • MGO Global Inc. • Apparel & other finishd prods of fabrics & similar matl • Florida
Contract Type FiledMay 15th, 2023 Company Industry JurisdictionTHIS COMMERCIAL LICENSE AGREEMENT ("Agreement"), dated and effective as of May 11, 2023 (the "Effective Date"), is made by and between MGO Global Inc. (“Licensee”), a Delaware corporation with its principal place of business at 1515 SE 17th Street, Suite 121, Fort Lauderdale, FL 33346 and Stand CO LLC (“Licensor” or “Stand”) a Utah limited liability company 11493 S Andover Road, South Jordan, UT 84095. The Licensee and Licensor may be referred to herein each, individually, as a “Party” and, collectively as the “Parties.”
COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • February 3rd, 2012 • BioAmber Inc. • Industrial organic chemicals
Contract Type FiledFebruary 3rd, 2012 Company IndustryThis Commercial License Agreement (“Commercial License”), effective the 15th day of April, 2010 (“Effective Date”), is made by and between Cargill, Inc., through its [***], having its principal place of business at [***] (hereinafter “Cargill”), and Bioamber S.A.S., having a place of business at Route de Bazancourt, F-51110, Pomacle France (“Bioamber”). Cargill and Bioamber are referred to herein as “Parties”, in singular or plural usage, as required by context.
Commercial License AgreementCommercial License Agreement • October 31st, 2014
Contract Type FiledOctober 31st, 2014This non-exclusive license grants you certain rights to use the product and is not an agreement for sale of the art work or accompanied documentation or any portion of it. The product and accompanied documentation may not be sublicensed, sold, leased, rented, lent, or given away to another person or entity.
COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • January 23rd, 2009 • Inovio Biomedical Corp • Surgical & medical instruments & apparatus • Delaware
Contract Type FiledJanuary 23rd, 2009 Company Industry JurisdictionThis Agreement is effective as of the latest date of signing below and is by and between Dow Global Technologies Incorporated (“Dow”), a Delaware corporation having its principal offices at 2030 Dow Center, Midland, MI, 48674 USA and VGX Pharmaceuticals, Inc, a Delaware corporation (“VGX”) having a principal place of business at 450 Sentry Parkway, Blue Bell, PA 19422.
COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • February 14th, 2007 • Senesco Technologies Inc • Services-commercial physical & biological research • New York
Contract Type FiledFebruary 14th, 2007 Company Industry JurisdictionTHIS AGREEMENT (“Agreement”) dated as of December 21, 2006 (“Effective Date”) is entered into by and between SENESCO TECHNOLOGIES, INC, a Delaware corporation with principal offices at 303 George Street, Suite 420, New Brunswick, NJ 08901 (“STI”) and ARBORGEN, LLC, a Delaware limited liability company with principle offices at 180 Westvaco Rd., Summerville, SC 29484 (“AG”).
COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • November 23rd, 2021
Contract Type FiledNovember 23rd, 2021hereafter named the [LICENSEE] and sets out the Terms & Conditions of use for the digital resource, Vodou: Theology of Liberation documentary [hereafter named FILM].
AMENDMENT NO. 1 TO COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • March 16th, 2020 • Oncternal Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledMarch 16th, 2020 Company IndustryThis Amendment No. 1 to Commercial License Agreement (the “Amendment”), effective as of February 5, 2020 (the “Amendment Effective Date”), is by and between SELEXIS SA (“SELEXIS”) and Oncternal Therapeutics, Inc. (“COMPANY”).
COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • August 7th, 2023 • Sage Therapeutics, Inc. • Pharmaceutical preparations • California
Contract Type FiledAugust 7th, 2023 Company Industry JurisdictionCYDEX PHARMACEUTICALS, INC., a Delaware corporation with offices at 11119 North Torrey Pines Road, Suite 200, La Jolla, California 92037 (“CyDex”); and
mPING View Reports Access Documentation mPING License Details LICENSE mPING TERMS OF USE AND NON-COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • May 5th, 2020
Contract Type FiledMay 5th, 2020This Agreement ("Agreement"), effective as of the date on which the LICENSEE accesses the WEBSITE and/or the PROGRAM ("Effective Date"), and is by and between you as the user ("LICENSEE," as this term is further defined herein below); and the Board of Regents of the University of Oklahoma, a constitutional state entity of the State of Oklahoma, by and through the Office of Technology Development located at 301 David L. Boren Boulevard, Suite 3120, Norman, Oklahoma, 73019 ("UNIVERSITY"); and User Centric IP, LP ("IP LICENSOR") located 385 Science Park Road, State College, Pennsylvania 16803 [(405) 359-0773]. LICENSEE, UNIVERSITY and IP LICENSOR may be referred to herein in the singular as a "Party" and collectively as the "Parties."
COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • March 8th, 2010 • Nautilus, Inc. • Sporting & athletic goods, nec • Washington
Contract Type FiledMarch 8th, 2010 Company Industry JurisdictionTHIS LICENSE AGREEMENT (hereinafter “License” or “Agreement”) is by and between Med-Fit Systems, Inc. a California corporation (“Buyer”) and Nautilus, Inc., a Washington corporation (“Nautilus”) (collectively the “Parties”). This License is an exhibit to an Asset Purchase Agreement (the “APA”) entered into on the same date between the Parties.
NServiceBus Commercial License AgreementCommercial License Agreement • April 10th, 2014 • New York
Contract Type FiledApril 10th, 2014 JurisdictionPLEASE READ THIS AGREEMENT CAREFULLY. BY CHECKING THE BOX "I AGREE", MAKING A PURCHASE OR INSTALLING OR USING ALL OR ANY PORTION OF THE NSERVICEBUS SOFTWARE (DEFINED BELOW), YOU, ON YOUR OWN BEHALF AS AN INDIVIDUAL, AND ON BEHALF OF YOUR EMPLOYER OR ANOTHER ENTITY WHICH HAS NOT YET DONE SO (COLLECTIVELY "YOU" OR "CUSTOMER"), ARE ACCEPTING ALL OF THE TERMS AND CONDITIONS SET FORTH BELOW ("AGREEMENT") WITH NSERVICEBUS LTD. (DOING BUSINESS AS PARTICULAR SOFTWARE) ("NSB"). IF YOU DO NOT AGREE TO ALL OF THESE TERMS AND CONDITIONS, DO NOT PURCHASE THIS SOFTWARE. YOU WILL NOT BE GIVEN ACCESS TO THE SOFTWARE UNLESS YOU ACCEPT THE TERMS OF THIS AGREEMENT. IF YOU WISH TO USE THE SOFTWARE AS AN EMPLOYEE, CONTRACTOR, OR AGENT OF A CORPORATION, PARTNERSHIP OR SIMILAR ENTITY, THEN YOU MUST BE AUTHORIZED TO SIGN FOR AND BIND THE ENTITY IN ORDER TO ACCEPT THE TERMS OF THIS AGREEMENT. THE LICENSES GRANTED UNDER THIS AGREEMENT ARE EXPRESSLY CONDITIONED UPON ACCEPTANCE BY SUCHAUTHORIZED PERSONNEL. IF YOU
LICENSE AGREEMENTCommercial License Agreement • November 8th, 2011 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • California
Contract Type FiledNovember 8th, 2011 Company Industry Jurisdiction*** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
AMENDMENT NO. 2 TO COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • November 14th, 2005 • Xenogen Corp • Measuring & controlling devices, nec
Contract Type FiledNovember 14th, 2005 Company IndustryTHIS AMENDMENT NO. 2 (“Amendment No. 2”), effective as of October 4, 2005 (the “Amendment Effective Date”), is made by and between Xenogen Corporation, having its principal place of business at 860 Atlantic Avenue, Alameda, California 94501 (“Xenogen”) and Novartis Institutes for BioMedical Research, Inc., having its principal place of business at 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (“NIBRI”).
CONFIDENTIAL TREATMENT REQUESTED. CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION.]Commercial License Agreement • May 3rd, 2004 • Xenogen Corp • Services-commercial physical & biological research • California
Contract Type FiledMay 3rd, 2004 Company Industry JurisdictionThis Agreement (the “Agreement”) effective as of July 12, 2000 (the “Effective Date”) is made by and between Xenogen Corporation, having a principal place of business at 860 Atlantic Avenue, Alameda, California 94501 (“Xenogen”) and IRM, LLC, a Delaware Corporation, (“IRM”), having a principal place of business at Sofia House, 48 Church Street, Hamilton, Bermuda.
Commercial License AgreementCommercial License Agreement • March 2nd, 2024
Contract Type FiledMarch 2nd, 2024This document constitutes a commercial license agreement between Shadowfall Workshop (the Seller) and the Buyer for the use of 3D models, subject to the terms outlined below. The key points of this agreement include:
COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • September 10th, 2020 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • California
Contract Type FiledSeptember 10th, 2020 Company Industry JurisdictionThis Commercial License Agreement (this “Agreement”) is entered into effective September 9, 2020 (the “Effective Date”) by Taurus Biosciences, LLC, a Delaware limited liability company (“Taurus”), and Minotaur Therapeutics, Inc., a California corporation (inclusive of any and all current and future Controlled Affiliates, “Licensee”), on the other hand. Each Controlled Affiliate is also a party to this Agreement.
COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • May 12th, 2023 • Oragenics Inc • Pharmaceutical preparations • Delaware
Contract Type FiledMay 12th, 2023 Company Industry JurisdictionThis COMMERCIAL LICENSE Agreement (the “Agreement”) is made and entered into effective as of February 21, 2023 (the “Effective Date”) by and between INSPIREVAX INC., a corporation incorporated in accordance with the federal laws of Canada, with a registered office at 46 rue de Saint-Tropez, Kirkland, Québec, Canada, H9J 2K6 (“Inspirevax”), and Oragenics, Inc., a Florida corporation having its principal place of business at 4902 Eisenhower Blvd., Suite 125, Tampa, FL 33634 (“Oragenics”). Inspirevax and Oragenics may be referred to herein individually as a “Party”, and collectively as the “Parties.”